Bruker Corp (BRKRP) Cash & Equivalents (2010 - 2026)

Bruker (BRKRP) has 17 years of Cash & Equivalents data on file, last reported at $133.4 million in Q1 2026.

• Quarterly Cash & Equivalents fell 27.58% year-over-year to $133.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $133.4 million (down 27.58% YoY) and the FY2025 annual result came in at $298.8 million, up 62.92% from the prior year.
• Cash & Equivalents retreated to $133.4 million in Q1 2026, from $298.8 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $816.1 million in Q1 2022 to a low of $92.0 million in Q2 2025.
• A 5-year average of $392.8 million and a median of $340.1 million in 2024 frame the typical range for Cash & Equivalents.
• Annual changes were most pronounced in 2024 — Cash & Equivalents sank 70.48% — and 2025, when it soared 97.91%.
• Tracing BRKRP's Cash & Equivalents over 5 years: stood at $645.5 million in 2022, then retreated by 24.35% to $488.3 million in 2023, then sank by 62.44% to $183.4 million in 2024, then jumped by 62.92% to $298.8 million in 2025, then tumbled by 55.35% to $133.4 million in 2026.
• The last three Cash & Equivalents figures came in at $133.4 million (Q1 2026), $298.8 million (Q4 2025), and $293.1 million (Q3 2025), per Business Quant data.